Qilian International Holding Group Limited
Qilian International Holding Group Limited (QLI) Stock Competitors & Peer Comparison
See (QLI) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| QLI | $5.41 | -3.57% | 38.7M | -4.92 | -$1.10 | N/A |
| ZTS | $152.82 | -0.41% | 68.1B | 27.50 | $5.56 | +1.26% |
| TAK | $14.66 | -0.54% | 46.3B | 63.70 | $0.23 | +4.02% |
| HLN | $9.85 | +1.03% | 44.3B | 23.48 | $0.42 | +1.71% |
| TEVA | $16.33 | -1.51% | 18.8B | -14.22 | -$1.15 | N/A |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| NBIX | $131.64 | -1.51% | 13B | 44.62 | $2.95 | N/A |
| RDY | $14.71 | +0.75% | 12.2B | 18.62 | $0.79 | +0.65% |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| VTRS | $9.35 | -0.21% | 11B | -2.94 | -$3.18 | +5.15% |
Stock Comparison
QLI vs ZTS Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, ZTS has a market cap of 68.1B. Regarding current trading prices, QLI is priced at $5.41, while ZTS trades at $152.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas ZTS's P/E ratio is 27.50. In terms of profitability, QLI's ROE is -0.16%, compared to ZTS's ROE of +0.51%. Regarding short-term risk, QLI is less volatile compared to ZTS. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check ZTS's competition here
QLI vs TAK Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, TAK has a market cap of 46.3B. Regarding current trading prices, QLI is priced at $5.41, while TAK trades at $14.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas TAK's P/E ratio is 63.70. In terms of profitability, QLI's ROE is -0.16%, compared to TAK's ROE of +0.04%. Regarding short-term risk, QLI is less volatile compared to TAK. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check TAK's competition here
QLI vs HLN Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, HLN has a market cap of 44.3B. Regarding current trading prices, QLI is priced at $5.41, while HLN trades at $9.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas HLN's P/E ratio is 23.48. In terms of profitability, QLI's ROE is -0.16%, compared to HLN's ROE of +0.09%. Regarding short-term risk, QLI is less volatile compared to HLN. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check HLN's competition here
QLI vs TEVA Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, TEVA has a market cap of 18.8B. Regarding current trading prices, QLI is priced at $5.41, while TEVA trades at $16.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas TEVA's P/E ratio is -14.22. In terms of profitability, QLI's ROE is -0.16%, compared to TEVA's ROE of -0.21%. Regarding short-term risk, QLI is less volatile compared to TEVA. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check TEVA's competition here
QLI vs ITCI Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, QLI is priced at $5.41, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas ITCI's P/E ratio is -180.64. In terms of profitability, QLI's ROE is -0.16%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, QLI and ITCI have similar daily volatility (0.00).Check ITCI's competition here
QLI vs NBIX Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, NBIX has a market cap of 13B. Regarding current trading prices, QLI is priced at $5.41, while NBIX trades at $131.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas NBIX's P/E ratio is 44.62. In terms of profitability, QLI's ROE is -0.16%, compared to NBIX's ROE of +0.12%. Regarding short-term risk, QLI is less volatile compared to NBIX. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check NBIX's competition here
QLI vs RDY Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, RDY has a market cap of 12.2B. Regarding current trading prices, QLI is priced at $5.41, while RDY trades at $14.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas RDY's P/E ratio is 18.62. In terms of profitability, QLI's ROE is -0.16%, compared to RDY's ROE of +0.18%. Regarding short-term risk, QLI is less volatile compared to RDY. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check RDY's competition here
QLI vs CTLT Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, QLI is priced at $5.41, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas CTLT's P/E ratio is -27.84. In terms of profitability, QLI's ROE is -0.16%, compared to CTLT's ROE of -0.11%. Regarding short-term risk, QLI is less volatile compared to CTLT. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check CTLT's competition here
QLI vs VTRS Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, VTRS has a market cap of 11B. Regarding current trading prices, QLI is priced at $5.41, while VTRS trades at $9.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas VTRS's P/E ratio is -2.94. In terms of profitability, QLI's ROE is -0.16%, compared to VTRS's ROE of -0.21%. Regarding short-term risk, QLI is less volatile compared to VTRS. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check VTRS's competition here
QLI vs RGC Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, RGC has a market cap of 7.5B. Regarding current trading prices, QLI is priced at $5.41, while RGC trades at $15.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas RGC's P/E ratio is -1518.00. In terms of profitability, QLI's ROE is -0.16%, compared to RGC's ROE of -0.50%. Regarding short-term risk, QLI is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check RGC's competition here
QLI vs ELAN Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, ELAN has a market cap of 7.3B. Regarding current trading prices, QLI is priced at $5.41, while ELAN trades at $14.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas ELAN's P/E ratio is 19.58. In terms of profitability, QLI's ROE is -0.16%, compared to ELAN's ROE of +0.06%. Regarding short-term risk, QLI is less volatile compared to ELAN. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check ELAN's competition here
QLI vs LNTH Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, LNTH has a market cap of 4.9B. Regarding current trading prices, QLI is priced at $5.41, while LNTH trades at $70.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas LNTH's P/E ratio is 20.21. In terms of profitability, QLI's ROE is -0.16%, compared to LNTH's ROE of +0.23%. Regarding short-term risk, QLI is less volatile compared to LNTH. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check LNTH's competition here
QLI vs PRGO Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, PRGO has a market cap of 3.9B. Regarding current trading prices, QLI is priced at $5.41, while PRGO trades at $28.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas PRGO's P/E ratio is -23.42. In terms of profitability, QLI's ROE is -0.16%, compared to PRGO's ROE of -0.04%. Regarding short-term risk, QLI is less volatile compared to PRGO. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check PRGO's competition here
QLI vs AMRX Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, AMRX has a market cap of 3.7B. Regarding current trading prices, QLI is priced at $5.41, while AMRX trades at $8.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas AMRX's P/E ratio is -200.13. In terms of profitability, QLI's ROE is -0.16%, compared to AMRX's ROE of -0.07%. Regarding short-term risk, QLI is less volatile compared to AMRX. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check AMRX's competition here
QLI vs HCM Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, HCM has a market cap of 3.1B. Regarding current trading prices, QLI is priced at $5.41, while HCM trades at $17.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas HCM's P/E ratio is 88.90. In terms of profitability, QLI's ROE is -0.16%, compared to HCM's ROE of +0.05%. Regarding short-term risk, QLI is less volatile compared to HCM. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check HCM's competition here
QLI vs ALVOW Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, ALVOW has a market cap of 2.8B. Regarding current trading prices, QLI is priced at $5.41, while ALVOW trades at $1.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas ALVOW's P/E ratio is N/A. In terms of profitability, QLI's ROE is -0.16%, compared to ALVOW's ROE of -0.23%. Regarding short-term risk, QLI is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check ALVOW's competition here
QLI vs ALVO Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, ALVO has a market cap of 2.8B. Regarding current trading prices, QLI is priced at $5.41, while ALVO trades at $9.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas ALVO's P/E ratio is 24.78. In terms of profitability, QLI's ROE is -0.16%, compared to ALVO's ROE of -0.23%. Regarding short-term risk, QLI is less volatile compared to ALVO. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check ALVO's competition here
QLI vs BHC Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, BHC has a market cap of 2.5B. Regarding current trading prices, QLI is priced at $5.41, while BHC trades at $6.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas BHC's P/E ratio is -56.46. In terms of profitability, QLI's ROE is -0.16%, compared to BHC's ROE of +0.05%. Regarding short-term risk, QLI is less volatile compared to BHC. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check BHC's competition here
QLI vs DCPH Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, QLI is priced at $5.41, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas DCPH's P/E ratio is -11.58. In terms of profitability, QLI's ROE is -0.16%, compared to DCPH's ROE of -0.28%. Regarding short-term risk, QLI is less volatile compared to DCPH. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check DCPH's competition here
QLI vs BGM Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, BGM has a market cap of 2.2B. Regarding current trading prices, QLI is priced at $5.41, while BGM trades at $10.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas BGM's P/E ratio is -54.75. In terms of profitability, QLI's ROE is -0.16%, compared to BGM's ROE of -0.03%. Regarding short-term risk, QLI is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check BGM's competition here
QLI vs INDV Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, INDV has a market cap of 2.1B. Regarding current trading prices, QLI is priced at $5.41, while INDV trades at $16.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas INDV's P/E ratio is -336.20. In terms of profitability, QLI's ROE is -0.16%, compared to INDV's ROE of -0.01%. Regarding short-term risk, QLI is less volatile compared to INDV. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check INDV's competition here
QLI vs EMBCV Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, QLI is priced at $5.41, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas EMBCV's P/E ratio is N/A. In terms of profitability, QLI's ROE is -0.16%, compared to EMBCV's ROE of -0.07%. Regarding short-term risk, QLI is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check EMBCV's competition here
QLI vs SUPN Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, SUPN has a market cap of 1.8B. Regarding current trading prices, QLI is priced at $5.41, while SUPN trades at $32.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas SUPN's P/E ratio is 29.60. In terms of profitability, QLI's ROE is -0.16%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, QLI is less volatile compared to SUPN. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check SUPN's competition here
QLI vs TARO Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, QLI is priced at $5.41, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas TARO's P/E ratio is 30.05. In terms of profitability, QLI's ROE is -0.16%, compared to TARO's ROE of +0.02%. Regarding short-term risk, QLI is less volatile compared to TARO. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check TARO's competition here
QLI vs ANIP Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, ANIP has a market cap of 1.4B. Regarding current trading prices, QLI is priced at $5.41, while ANIP trades at $66.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas ANIP's P/E ratio is -56.58. In terms of profitability, QLI's ROE is -0.16%, compared to ANIP's ROE of -0.05%. Regarding short-term risk, QLI is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check ANIP's competition here
QLI vs EVO Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, EVO has a market cap of 1.4B. Regarding current trading prices, QLI is priced at $5.41, while EVO trades at $4.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas EVO's P/E ratio is -5.96. In terms of profitability, QLI's ROE is -0.16%, compared to EVO's ROE of -0.22%. Regarding short-term risk, QLI is less volatile compared to EVO. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check EVO's competition here
QLI vs HROW Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, QLI is priced at $5.41, while HROW trades at $37.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas HROW's P/E ratio is -61.11. In terms of profitability, QLI's ROE is -0.16%, compared to HROW's ROE of -0.36%. Regarding short-term risk, QLI is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check HROW's competition here
QLI vs DVAX Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, DVAX has a market cap of 1.3B. Regarding current trading prices, QLI is priced at $5.41, while DVAX trades at $11.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas DVAX's P/E ratio is -22.32. In terms of profitability, QLI's ROE is -0.16%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, QLI is less volatile compared to DVAX. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check DVAX's competition here
QLI vs FLXN Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, FLXN has a market cap of 1.3B. Regarding current trading prices, QLI is priced at $5.41, while FLXN trades at $25.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas FLXN's P/E ratio is N/A. In terms of profitability, QLI's ROE is -0.16%, compared to FLXN's ROE of +6.19%. Regarding short-term risk, QLI and FLXN have similar daily volatility (0.00).Check FLXN's competition here
QLI vs PAHC Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, PAHC has a market cap of 1.2B. Regarding current trading prices, QLI is priced at $5.41, while PAHC trades at $29.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas PAHC's P/E ratio is 37.65. In terms of profitability, QLI's ROE is -0.16%, compared to PAHC's ROE of +0.12%. Regarding short-term risk, QLI is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check PAHC's competition here
QLI vs AVDL Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, AVDL has a market cap of 1.1B. Regarding current trading prices, QLI is priced at $5.41, while AVDL trades at $11.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas AVDL's P/E ratio is -43.25. In terms of profitability, QLI's ROE is -0.16%, compared to AVDL's ROE of -0.36%. Regarding short-term risk, QLI is less volatile compared to AVDL. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check AVDL's competition here
QLI vs AMPH Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, AMPH has a market cap of 1.1B. Regarding current trading prices, QLI is priced at $5.41, while AMPH trades at $22.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas AMPH's P/E ratio is 8.16. In terms of profitability, QLI's ROE is -0.16%, compared to AMPH's ROE of +0.19%. Regarding short-term risk, QLI is less volatile compared to AMPH. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check AMPH's competition here
QLI vs COLL Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, COLL has a market cap of 1B. Regarding current trading prices, QLI is priced at $5.41, while COLL trades at $32.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas COLL's P/E ratio is 26.34. In terms of profitability, QLI's ROE is -0.16%, compared to COLL's ROE of +0.19%. Regarding short-term risk, QLI is less volatile compared to COLL. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check COLL's competition here
QLI vs PCRX Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, QLI is priced at $5.41, while PCRX trades at $21.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas PCRX's P/E ratio is -9.74. In terms of profitability, QLI's ROE is -0.16%, compared to PCRX's ROE of -0.13%. Regarding short-term risk, QLI is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check PCRX's competition here
QLI vs PETQ Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, QLI is priced at $5.41, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas PETQ's P/E ratio is 83.73. In terms of profitability, QLI's ROE is -0.16%, compared to PETQ's ROE of +0.05%. Regarding short-term risk, QLI is less volatile compared to PETQ. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check PETQ's competition here
QLI vs CRON Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, CRON has a market cap of 797.8M. Regarding current trading prices, QLI is priced at $5.41, while CRON trades at $2.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas CRON's P/E ratio is 14.79. In terms of profitability, QLI's ROE is -0.16%, compared to CRON's ROE of +0.05%. Regarding short-term risk, QLI is less volatile compared to CRON. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check CRON's competition here
QLI vs TLRY Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, TLRY has a market cap of 729.6M. Regarding current trading prices, QLI is priced at $5.41, while TLRY trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas TLRY's P/E ratio is -0.64. In terms of profitability, QLI's ROE is -0.16%, compared to TLRY's ROE of -0.29%. Regarding short-term risk, QLI is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check TLRY's competition here
QLI vs EMBC Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, EMBC has a market cap of 665.1M. Regarding current trading prices, QLI is priced at $5.41, while EMBC trades at $11.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas EMBC's P/E ratio is 12.79. In terms of profitability, QLI's ROE is -0.16%, compared to EMBC's ROE of -0.07%. Regarding short-term risk, QLI is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check EMBC's competition here
QLI vs EOLS Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, EOLS has a market cap of 621.5M. Regarding current trading prices, QLI is priced at $5.41, while EOLS trades at $9.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas EOLS's P/E ratio is -10.83. In terms of profitability, QLI's ROE is -0.16%, compared to EOLS's ROE of -9.32%. Regarding short-term risk, QLI is less volatile compared to EOLS. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check EOLS's competition here
QLI vs ORGO Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, ORGO has a market cap of 602.6M. Regarding current trading prices, QLI is priced at $5.41, while ORGO trades at $4.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas ORGO's P/E ratio is -29.69. In terms of profitability, QLI's ROE is -0.16%, compared to ORGO's ROE of -0.06%. Regarding short-term risk, QLI is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check ORGO's competition here
QLI vs BDSI Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, QLI is priced at $5.41, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas BDSI's P/E ratio is 6.82. In terms of profitability, QLI's ROE is -0.16%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, QLI is less volatile compared to BDSI. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check BDSI's competition here
QLI vs SIGA Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, SIGA has a market cap of 504.4M. Regarding current trading prices, QLI is priced at $5.41, while SIGA trades at $7.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas SIGA's P/E ratio is 10.54. In terms of profitability, QLI's ROE is -0.16%, compared to SIGA's ROE of +0.25%. Regarding short-term risk, QLI is less volatile compared to SIGA. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check SIGA's competition here
QLI vs KMDA Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, KMDA has a market cap of 447.4M. Regarding current trading prices, QLI is priced at $5.41, while KMDA trades at $7.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas KMDA's P/E ratio is 27.79. In terms of profitability, QLI's ROE is -0.16%, compared to KMDA's ROE of +0.06%. Regarding short-term risk, QLI is less volatile compared to KMDA. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check KMDA's competition here
QLI vs AQST Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, AQST has a market cap of 417.7M. Regarding current trading prices, QLI is priced at $5.41, while AQST trades at $4.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas AQST's P/E ratio is -7.25. In terms of profitability, QLI's ROE is -0.16%, compared to AQST's ROE of +1.07%. Regarding short-term risk, QLI is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check AQST's competition here
QLI vs EBS Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, EBS has a market cap of 405.5M. Regarding current trading prices, QLI is priced at $5.41, while EBS trades at $7.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas EBS's P/E ratio is -2.90. In terms of profitability, QLI's ROE is -0.16%, compared to EBS's ROE of -0.27%. Regarding short-term risk, QLI is less volatile compared to EBS. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check EBS's competition here
QLI vs SNDL Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, SNDL has a market cap of 396.3M. Regarding current trading prices, QLI is priced at $5.41, while SNDL trades at $1.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas SNDL's P/E ratio is -5.13. In terms of profitability, QLI's ROE is -0.16%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, QLI is less volatile compared to SNDL. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check SNDL's competition here
QLI vs ALIM Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, QLI is priced at $5.41, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas ALIM's P/E ratio is 5.28. In terms of profitability, QLI's ROE is -0.16%, compared to ALIM's ROE of -0.32%. Regarding short-term risk, QLI is less volatile compared to ALIM. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check ALIM's competition here
QLI vs ESPR Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, ESPR has a market cap of 295.3M. Regarding current trading prices, QLI is priced at $5.41, while ESPR trades at $1.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas ESPR's P/E ratio is -1.75. In terms of profitability, QLI's ROE is -0.16%, compared to ESPR's ROE of +0.40%. Regarding short-term risk, QLI is less volatile compared to ESPR. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check ESPR's competition here
QLI vs TKNO Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, TKNO has a market cap of 276.3M. Regarding current trading prices, QLI is priced at $5.41, while TKNO trades at $5.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas TKNO's P/E ratio is -11.24. In terms of profitability, QLI's ROE is -0.16%, compared to TKNO's ROE of -0.28%. Regarding short-term risk, QLI is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check TKNO's competition here
QLI vs LFCR Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, LFCR has a market cap of 272.1M. Regarding current trading prices, QLI is priced at $5.41, while LFCR trades at $7.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas LFCR's P/E ratio is -5.00. In terms of profitability, QLI's ROE is -0.16%, compared to LFCR's ROE of -2.64%. Regarding short-term risk, QLI is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check LFCR's competition here
QLI vs ACB Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, ACB has a market cap of 270.5M. Regarding current trading prices, QLI is priced at $5.41, while ACB trades at $4.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas ACB's P/E ratio is 21.86. In terms of profitability, QLI's ROE is -0.16%, compared to ACB's ROE of +0.00%. Regarding short-term risk, QLI is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check ACB's competition here
QLI vs LNDC Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, QLI is priced at $5.41, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas LNDC's P/E ratio is -4.04. In terms of profitability, QLI's ROE is -0.16%, compared to LNDC's ROE of +2.28%. Regarding short-term risk, QLI is less volatile compared to LNDC. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check LNDC's competition here
QLI vs ZYBT Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, ZYBT has a market cap of 263M. Regarding current trading prices, QLI is priced at $5.41, while ZYBT trades at $5.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas ZYBT's P/E ratio is 185.00. In terms of profitability, QLI's ROE is -0.16%, compared to ZYBT's ROE of +0.11%. Regarding short-term risk, QLI is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check ZYBT's competition here
QLI vs CGC Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, CGC has a market cap of 230.5M. Regarding current trading prices, QLI is priced at $5.41, while CGC trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas CGC's P/E ratio is -0.27. In terms of profitability, QLI's ROE is -0.16%, compared to CGC's ROE of -1.13%. Regarding short-term risk, QLI is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check CGC's competition here
QLI vs TYHT Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, QLI is priced at $5.41, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas TYHT's P/E ratio is -1.61. In terms of profitability, QLI's ROE is -0.16%, compared to TYHT's ROE of -1.41%. Regarding short-term risk, QLI is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check TYHT's competition here
QLI vs OGI Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, OGI has a market cap of 203.5M. Regarding current trading prices, QLI is priced at $5.41, while OGI trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas OGI's P/E ratio is 11.69. In terms of profitability, QLI's ROE is -0.16%, compared to OGI's ROE of +0.05%. Regarding short-term risk, QLI is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check OGI's competition here
QLI vs SXTC Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, SXTC has a market cap of 188M. Regarding current trading prices, QLI is priced at $5.41, while SXTC trades at $1.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas SXTC's P/E ratio is 0.01. In terms of profitability, QLI's ROE is -0.16%, compared to SXTC's ROE of +0.47%. Regarding short-term risk, QLI is less volatile compared to SXTC. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check SXTC's competition here
QLI vs DERM Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, DERM has a market cap of 179M. Regarding current trading prices, QLI is priced at $5.41, while DERM trades at $7.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas DERM's P/E ratio is -20.77. In terms of profitability, QLI's ROE is -0.16%, compared to DERM's ROE of -0.52%. Regarding short-term risk, QLI is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check DERM's competition here
QLI vs REPH Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, QLI is priced at $5.41, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas REPH's P/E ratio is -8.04. In terms of profitability, QLI's ROE is -0.16%, compared to REPH's ROE of -0.22%. Regarding short-term risk, QLI is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check REPH's competition here
QLI vs BIOA Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, BIOA has a market cap of 168.5M. Regarding current trading prices, QLI is priced at $5.41, while BIOA trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas BIOA's P/E ratio is -2.37. In terms of profitability, QLI's ROE is -0.16%, compared to BIOA's ROE of -0.38%. Regarding short-term risk, QLI is less volatile compared to BIOA. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check BIOA's competition here
QLI vs IXHL Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, IXHL has a market cap of 152.7M. Regarding current trading prices, QLI is priced at $5.41, while IXHL trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas IXHL's P/E ratio is -1.33. In terms of profitability, QLI's ROE is -0.16%, compared to IXHL's ROE of -2.03%. Regarding short-term risk, QLI is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check IXHL's competition here
QLI vs THTX Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, THTX has a market cap of 144.8M. Regarding current trading prices, QLI is priced at $5.41, while THTX trades at $3.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas THTX's P/E ratio is -16.58. In terms of profitability, QLI's ROE is -0.16%, compared to THTX's ROE of +0.38%. Regarding short-term risk, QLI is less volatile compared to THTX. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check THTX's competition here
QLI vs IRWD Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, IRWD has a market cap of 132.6M. Regarding current trading prices, QLI is priced at $5.41, while IRWD trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas IRWD's P/E ratio is -4.31. In terms of profitability, QLI's ROE is -0.16%, compared to IRWD's ROE of +0.10%. Regarding short-term risk, QLI is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check IRWD's competition here
QLI vs SCTL Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, QLI is priced at $5.41, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas SCTL's P/E ratio is -7.86. In terms of profitability, QLI's ROE is -0.16%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, QLI is less volatile compared to SCTL. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check SCTL's competition here
QLI vs CRDL Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, CRDL has a market cap of 115.7M. Regarding current trading prices, QLI is priced at $5.41, while CRDL trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas CRDL's P/E ratio is -4.12. In terms of profitability, QLI's ROE is -0.16%, compared to CRDL's ROE of -2.10%. Regarding short-term risk, QLI is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check CRDL's competition here
QLI vs PROC Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, PROC has a market cap of 114M. Regarding current trading prices, QLI is priced at $5.41, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas PROC's P/E ratio is 1.53. In terms of profitability, QLI's ROE is -0.16%, compared to PROC's ROE of -2.22%. Regarding short-term risk, QLI is less volatile compared to PROC. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check PROC's competition here
QLI vs OPTN Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, QLI is priced at $5.41, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas OPTN's P/E ratio is -4.42. In terms of profitability, QLI's ROE is -0.16%, compared to OPTN's ROE of +0.64%. Regarding short-term risk, QLI and OPTN have similar daily volatility (0.00).Check OPTN's competition here
QLI vs ZOM Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, QLI is priced at $5.41, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas ZOM's P/E ratio is -1.62. In terms of profitability, QLI's ROE is -0.16%, compared to ZOM's ROE of -0.55%. Regarding short-term risk, QLI is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check ZOM's competition here
QLI vs GRVI Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, QLI is priced at $5.41, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas GRVI's P/E ratio is 26.05. In terms of profitability, QLI's ROE is -0.16%, compared to GRVI's ROE of +0.28%. Regarding short-term risk, QLI is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check GRVI's competition here
QLI vs INCR Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, INCR has a market cap of 84.5M. Regarding current trading prices, QLI is priced at $5.41, while INCR trades at $1.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas INCR's P/E ratio is -3.52. In terms of profitability, QLI's ROE is -0.16%, compared to INCR's ROE of -0.07%. Regarding short-term risk, QLI is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check INCR's competition here
QLI vs QNTM Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, QNTM has a market cap of 81.6M. Regarding current trading prices, QLI is priced at $5.41, while QNTM trades at $23.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas QNTM's P/E ratio is -1.80. In terms of profitability, QLI's ROE is -0.16%, compared to QNTM's ROE of -1.88%. Regarding short-term risk, QLI is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check QNTM's competition here
QLI vs ASRT Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, ASRT has a market cap of 71.8M. Regarding current trading prices, QLI is priced at $5.41, while ASRT trades at $0.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas ASRT's P/E ratio is -2.34. In terms of profitability, QLI's ROE is -0.16%, compared to ASRT's ROE of -0.24%. Regarding short-term risk, QLI is less volatile compared to ASRT. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check ASRT's competition here
QLI vs ZYNE Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, QLI is priced at $5.41, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, QLI's ROE is -0.16%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, QLI is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check ZYNE's competition here
QLI vs SSIC Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, QLI is priced at $5.41, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas SSIC's P/E ratio is 11.93. In terms of profitability, QLI's ROE is -0.16%, compared to SSIC's ROE of +0.09%. Regarding short-term risk, QLI is less volatile compared to SSIC. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check SSIC's competition here
QLI vs VLNS Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, QLI is priced at $5.41, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas VLNS's P/E ratio is -1.03. In terms of profitability, QLI's ROE is -0.16%, compared to VLNS's ROE of N/A. Regarding short-term risk, QLI is less volatile compared to VLNS. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check VLNS's competition here
QLI vs CPIX Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, CPIX has a market cap of 50.3M. Regarding current trading prices, QLI is priced at $5.41, while CPIX trades at $3.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas CPIX's P/E ratio is -14.00. In terms of profitability, QLI's ROE is -0.16%, compared to CPIX's ROE of -0.13%. Regarding short-term risk, QLI is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check CPIX's competition here
QLI vs JUPW Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, QLI is priced at $5.41, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas JUPW's P/E ratio is -2.41. In terms of profitability, QLI's ROE is -0.16%, compared to JUPW's ROE of -9.40%. Regarding short-term risk, QLI is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check JUPW's competition here
QLI vs KALA Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, KALA has a market cap of 45.2M. Regarding current trading prices, QLI is priced at $5.41, while KALA trades at $7.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas KALA's P/E ratio is -0.95. In terms of profitability, QLI's ROE is -0.16%, compared to KALA's ROE of -3.69%. Regarding short-term risk, QLI is less volatile compared to KALA. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check KALA's competition here
QLI vs EGRX Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, EGRX has a market cap of 40.8M. Regarding current trading prices, QLI is priced at $5.41, while EGRX trades at $3.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas EGRX's P/E ratio is 3.71. In terms of profitability, QLI's ROE is -0.16%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, QLI is less volatile compared to EGRX. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check EGRX's competition here
QLI vs RMTI Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, RMTI has a market cap of 38.3M. Regarding current trading prices, QLI is priced at $5.41, while RMTI trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas RMTI's P/E ratio is -112.00. In terms of profitability, QLI's ROE is -0.16%, compared to RMTI's ROE of -0.01%. Regarding short-term risk, QLI is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check RMTI's competition here
QLI vs HEXO Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, QLI is priced at $5.41, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas HEXO's P/E ratio is -0.26. In terms of profitability, QLI's ROE is -0.16%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, QLI is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check HEXO's competition here
QLI vs SCYX Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, SCYX has a market cap of 28.8M. Regarding current trading prices, QLI is priced at $5.41, while SCYX trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas SCYX's P/E ratio is -1.32. In terms of profitability, QLI's ROE is -0.16%, compared to SCYX's ROE of -0.48%. Regarding short-term risk, QLI is less volatile compared to SCYX. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check SCYX's competition here
QLI vs CYTH Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, QLI is priced at $5.41, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas CYTH's P/E ratio is -0.80. In terms of profitability, QLI's ROE is -0.16%, compared to CYTH's ROE of +7.50%. Regarding short-term risk, QLI and CYTH have similar daily volatility (0.00).Check CYTH's competition here
QLI vs GELS Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, GELS has a market cap of 18.8M. Regarding current trading prices, QLI is priced at $5.41, while GELS trades at $1.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas GELS's P/E ratio is -5.34. In terms of profitability, QLI's ROE is -0.16%, compared to GELS's ROE of -0.07%. Regarding short-term risk, QLI is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check GELS's competition here
QLI vs DRRX Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, DRRX has a market cap of 18.2M. Regarding current trading prices, QLI is priced at $5.41, while DRRX trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas DRRX's P/E ratio is -1.22. In terms of profitability, QLI's ROE is -0.16%, compared to DRRX's ROE of -0.93%. Regarding short-term risk, QLI is less volatile compared to DRRX. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check DRRX's competition here
QLI vs PRPH Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, PRPH has a market cap of 17.5M. Regarding current trading prices, QLI is priced at $5.41, while PRPH trades at $0.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas PRPH's P/E ratio is -0.19. In terms of profitability, QLI's ROE is -0.16%, compared to PRPH's ROE of -1.65%. Regarding short-term risk, QLI is less volatile compared to PRPH. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check PRPH's competition here
QLI vs COSM Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, COSM has a market cap of 17.2M. Regarding current trading prices, QLI is priced at $5.41, while COSM trades at $0.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas COSM's P/E ratio is -0.54. In terms of profitability, QLI's ROE is -0.16%, compared to COSM's ROE of -0.51%. Regarding short-term risk, QLI is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check COSM's competition here
QLI vs AYTU Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, AYTU has a market cap of 16.3M. Regarding current trading prices, QLI is priced at $5.41, while AYTU trades at $2.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas AYTU's P/E ratio is -1.78. In terms of profitability, QLI's ROE is -0.16%, compared to AYTU's ROE of +0.05%. Regarding short-term risk, QLI is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check AYTU's competition here
QLI vs ACRX Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, QLI is priced at $5.41, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas ACRX's P/E ratio is -0.31. In terms of profitability, QLI's ROE is -0.16%, compared to ACRX's ROE of -2.49%. Regarding short-term risk, QLI is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check ACRX's competition here
QLI vs FLGC Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, FLGC has a market cap of 13.8M. Regarding current trading prices, QLI is priced at $5.41, while FLGC trades at $0.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas FLGC's P/E ratio is -0.64. In terms of profitability, QLI's ROE is -0.16%, compared to FLGC's ROE of -2.55%. Regarding short-term risk, QLI is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check FLGC's competition here
QLI vs TXMD Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, TXMD has a market cap of 13.2M. Regarding current trading prices, QLI is priced at $5.41, while TXMD trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas TXMD's P/E ratio is -6.00. In terms of profitability, QLI's ROE is -0.16%, compared to TXMD's ROE of -0.08%. Regarding short-term risk, QLI is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check TXMD's competition here
QLI vs BFRI Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, BFRI has a market cap of 11.2M. Regarding current trading prices, QLI is priced at $5.41, while BFRI trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas BFRI's P/E ratio is -1.36. In terms of profitability, QLI's ROE is -0.16%, compared to BFRI's ROE of -2.16%. Regarding short-term risk, QLI is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check BFRI's competition here
QLI vs AGRX Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, QLI is priced at $5.41, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas AGRX's P/E ratio is -0.89. In terms of profitability, QLI's ROE is -0.16%, compared to AGRX's ROE of +0.93%. Regarding short-term risk, QLI is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check AGRX's competition here
QLI vs TLPH Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, TLPH has a market cap of 8.9M. Regarding current trading prices, QLI is priced at $5.41, while TLPH trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas TLPH's P/E ratio is -0.99. In terms of profitability, QLI's ROE is -0.16%, compared to TLPH's ROE of -1.29%. Regarding short-term risk, QLI is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check TLPH's competition here
QLI vs IMCC Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, IMCC has a market cap of 8.9M. Regarding current trading prices, QLI is priced at $5.41, while IMCC trades at $2.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas IMCC's P/E ratio is -2.08. In terms of profitability, QLI's ROE is -0.16%, compared to IMCC's ROE of -0.79%. Regarding short-term risk, QLI is less volatile compared to IMCC. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check IMCC's competition here
QLI vs YCBD Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, YCBD has a market cap of 8.2M. Regarding current trading prices, QLI is priced at $5.41, while YCBD trades at $0.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas YCBD's P/E ratio is 0.01. In terms of profitability, QLI's ROE is -0.16%, compared to YCBD's ROE of -0.01%. Regarding short-term risk, QLI is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check YCBD's competition here
QLI vs NLTX Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, QLI is priced at $5.41, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas NLTX's P/E ratio is -0.28. In terms of profitability, QLI's ROE is -0.16%, compared to NLTX's ROE of -0.49%. Regarding short-term risk, QLI is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check NLTX's competition here
QLI vs SISI Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, SISI has a market cap of 7.5M. Regarding current trading prices, QLI is priced at $5.41, while SISI trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas SISI's P/E ratio is N/A. In terms of profitability, QLI's ROE is -0.16%, compared to SISI's ROE of -1.41%. Regarding short-term risk, QLI is less volatile compared to SISI. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check SISI's competition here
QLI vs LCI Comparison July 2025
QLI plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, QLI stands at 38.7M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, QLI is priced at $5.41, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
QLI currently has a P/E ratio of -4.92, whereas LCI's P/E ratio is -0.04. In terms of profitability, QLI's ROE is -0.16%, compared to LCI's ROE of +1.66%. Regarding short-term risk, QLI is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for QLI.Check LCI's competition here